EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Modeling the Impact and Cost of a Culture-Dependent Molecular Test for Antimicrobial Resistance in Resource-Limited Settings

Joshua M Chevalier iD, Megan A Hansen, Benjamin Blumel iD, Veronicah Chuchu iD, Birgitta Gleeson, Cecilia Ferreyra, Shaukat Khan iD, Brooke E Nichols iD, Kyra H Grantz iD

Clinical Infectious Diseases · 2026

DOI: 10.1093/cid/ciaf236 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Infectious Diseases, 2026. Verfasst von Joshua M Chevalier und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Global Health, Amsterdam Institute for Global Health and Development, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherland…. Hauptthemen laut MEDLINE: Drug Resistance, Bacterial, Molecular Diagnostic Techniques, Sepsis, Bacteria. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: FIND, UK Department of Health and Social Care, Global AMR Innovation Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Limited diagnostic access in resource-limited settings contributes to poor health outcomes among bacterial sepsis patients and the spread of antimicrobial resistance (AMR). Molecular diagnostic profiling of AMR may enable faster targeting of antibiotic therapies, improving clinical outcomes, reducing AMR development, and saving costs.

Methods

We modeled the impact of a culture-dependent molecular test for pathogen identification and resistance testing among hospitalized bloodstream infection patients to guide effective and cost-efficient implementation of these tools. We evaluated patient mortality, antibiotic use, hospital-associated infections, hospital days, and costs under the standard of care (empiric therapy, blood culture, phenotypic susceptibility testing) compared with molecular diagnostics by varying culture and susceptibility testing coverage, culture turnaround time, and AMR prevalence.

Results

The greatest impact of the molecular test occurred with 100% diagnostic coverage, shorter culture turnaround time, and high AMR prevalence, reducing up to 6% of deaths (interquartile range [IQR], 0%–12.1%), 5% of hospital days (IQR, 0.1%–10.7%), and 21% of days on inappropriate antibiotic therapy (IQR, 18.2%–24.4%). The minimum cost per molecular test performed, offset by cost savings, ranged from $109 in India to $585 in South Africa across all modeled scenarios.

Conclusions

In high AMR burden settings with blood culture infrastructure supporting fast turnaround times, a molecular test could improve health outcomes of bloodstream infection. Impact is limited by delayed turnaround times and the effectiveness of empiric therapy. Molecular diagnostics implemented at $100 or less can generate healthcare-system cost savings, supporting their adoption to improve health outcomes and reduce AMR while remaining cost-neutral.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug Resistance, BacterialMolecular Diagnostic TechniquesSepsisBacteriaHumansAnti-Bacterial AgentsMicrobial Sensitivity TestsBlood CultureCross InfectionCost-Benefit AnalysisBacteremiaResource-Limited Settings

Stichwörter der Autor:innen

antibiotic therapyantimicrobial resistancebloodstream infectiondiagnosticsresource-limited settings

Substanzen

Anti-Bacterial Agents

Autor:innen und Institutionen

  • Department of Global Health, Amsterdam Institute for Global Health and Development, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
  • AMR Programme, FIND, Geneva, Switzerland.
  • Department of Impact, FIND, Geneva, Switzerland.
  • Department of Global Health, Boston University School of Public Health, Boston, Massachusetts, USA.
  • Wits Diagnostic Innovation Hub, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.

ORCID-Profile: Joshua M Chevalier, Benjamin Blumel, Veronicah Chuchu, Shaukat Khan, Brooke E Nichols, Kyra H Grantz

Förderung

  • FIND
  • UK Department of Health and Social Care
  • Global AMR Innovation Fund
  • One Health UK aid fund

Zitieren

APA

Chevalier, J. M., Hansen, M. A., Blumel, B., Chuchu, V., Gleeson, B., Ferreyra, C., Khan, S., Nichols, B. E., & Grantz, K. H. (2026). Modeling the Impact and Cost of a Culture-Dependent Molecular Test for Antimicrobial Resistance in Resource-Limited Settings. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciaf236

Vancouver

Chevalier JM, Hansen MA, Blumel B, Chuchu V, Gleeson B, Ferreyra C, et al. Modeling the Impact and Cost of a Culture-Dependent Molecular Test for Antimicrobial Resistance in Resource-Limited Settings. Clinical Infectious Diseases. 2026. doi:10.1093/cid/ciaf236

BibTeX
@article{Chevalier2026,
  author = {Chevalier, Joshua M and Hansen, Megan A and Blumel, Benjamin and Chuchu, Veronicah and Gleeson, Birgitta and Ferreyra, Cecilia and Khan, Shaukat and Nichols, Brooke E and Grantz, Kyra H},
  title = {Modeling the Impact and Cost of a Culture-Dependent Molecular Test for Antimicrobial Resistance in Resource-Limited Settings},
  journal = {Clinical Infectious Diseases},
  year = {2026},
  doi = {10.1093/cid/ciaf236}
}
Kostenlos starten →